Core Points - The company has conducted a review of its 2024 stock option incentive plan, confirming the legitimacy and qualifications of the incentive recipients [1][2] - The stock option grant date is set for August 25, 2025, with a predetermined price of 11.95 CNY per share [2] Group 1 - The review by the company's supervisory board is based on relevant laws and regulations, including the Company Law and the Securities Law [1] - The incentive recipients meet all qualifications as per the legal requirements and do not fall under any disqualifying conditions [2] - The supervisory board has approved the list of incentive recipients and the stock option grant arrangements [2]

Core Viewpoint - The company has announced that the conditions for the first exercise period of the 2024 stock option incentive plan have been met, allowing for the exercise of 1,007,000 stock options [1][9][11]. Group 1: Stock Option Plan Details - The stock options to be exercised amount to 1,007,000 shares, which will be sourced from the issuance of A-shares to the incentive recipients [1]. - The first exercise period for the stock options is set to last from 12 months after the grant date until the last trading day of the 24-month period, with a 50% exercise ratio [6][9]. - The performance assessment for the incentive plan covers the fiscal years 2024 and 2025, with specific revenue and profit growth targets set for each year [8][10]. Group 2: Performance Conditions - For the first exercise period, the company must achieve either a net profit growth of at least 11.43% or a revenue growth of no less than 7.00% compared to the previous year [8]. - The second exercise period will require a net profit growth of at least 15.00% or a similar revenue growth target [8]. Group 3: Approval and Compliance - The board of directors and the supervisory board have approved the necessary resolutions regarding the stock option plan and its implementation [2][4][10]. - The company has confirmed that all incentive recipients meet the eligibility criteria as per the relevant regulations and internal guidelines [10][11]. Group 4: Legal and Financial Advisory - Legal opinions confirm that the adjustments and actions taken regarding the stock option plan comply with applicable laws and regulations [12]. - The independent financial advisor has also verified that the conditions for the first exercise period have been met and that the necessary approvals have been obtained [12].

Core Points - The company has initiated its 2023 stock option incentive plan, with the first grant and reserved grant details disclosed [1][2][3] - A total of 338 eligible participants can exercise 15,946,000 stock options, representing 0.55% of the total share capital, at an exercise price of 9.36 yuan per share [1][6] - The reserved grant allows 9 eligible participants to exercise 302,500 stock options, accounting for 0.01% of the total share capital, also at an exercise price of 9.36 yuan per share [1][6] Approval Process - The stock option incentive plan underwent several board meetings for approval, including the review of the plan draft and management methods [2][3] - Independent directors and the supervisory board provided their consent and verification for the plan [2][3] Adjustments and Cancellations - The exercise price was adjusted from 9.73 yuan to 9.36 yuan due to the company's profit distribution plans [5] - A total of 2,200,000 stock options were canceled due to 19 participants leaving the company and 239,000 options due to performance assessment failures [5][6] Performance Conditions - The first exercise period is defined as starting from the first trading day after 20 months from the grant date until the last trading day within 32 months [6] - The performance conditions for exercising options include no adverse audit opinions and meeting specific financial performance metrics [6][8] Impact on Company - The exercise of these options is not expected to significantly impact the company's shareholding structure [16] - If all options are exercised, the total share capital will increase by 1,624,850 shares, with minimal effect on earnings per share and return on equity [16] Reporting and Compliance - The company will disclose changes in incentive participants, adjustments to stock option parameters, and exercise situations in regular or temporary reports [17]

Core Viewpoint - The company has approved the 2024 stock option incentive plan and confirmed the eligibility of the reserved grant recipients through a compliance review by the remuneration and assessment committee [1][2]. Disclosure and Review Process - The company held meetings on August 14, 2025, to discuss and approve the stock option incentive plan for 2024, including the list of reserved grant recipients [1]. - The remuneration and assessment committee verified the list of recipients, their identification documents, employment contracts, and positions held within the company and its subsidiaries [1]. - The public disclosure of the reserved grant recipients' names and positions was conducted in accordance with the relevant regulations [1]. Compliance with Regulations - The remuneration and assessment committee concluded that the public disclosure process for the 2024 stock option incentive plan was legal and compliant [2]. - All reserved grant recipients meet the qualifications set forth by relevant laws and regulations, ensuring their eligibility for the incentive plan [2].

Core Points - The company has announced the first exercise period of its 2024 stock option incentive plan, allowing 39 eligible participants to exercise a total of 2.71488 million stock options at a price of 21.20 yuan per share [1][2][3] - The exercise will be conducted through a self-exercise model, with the stock options sourced from a directed issuance of A-shares [1][2][3] - The exercise period is set from August 29, 2025, to August 28, 2026, and the company has completed the necessary registration with the Shenzhen Securities Registration and Clearing Company [2][3] Summary by Sections Stock Option Details - Stock option code: 036574, abbreviated as "Shanshui JLC1" [1][4] - Total number of stock options available for exercise: 2.71488 million [2][3] - Exercise price set at 21.20 yuan per share [3] Impact on Company - The exercise of stock options will not significantly affect the company's shareholding structure or its listing conditions [5] - The financial impact of the stock options will be minimal on basic earnings per share and return on equity, with expenses recognized according to accounting standards [5] - The company will use the funds raised from the exercise to supplement its working capital, and individual income tax will be handled through withholding by the company [5][6] Compliance and Reporting - The company has signed a service agreement with Guosen Securities for the self-exercise process, ensuring compliance with operational requirements [6] - Regular updates on the status of stock option exercises and changes in incentive participants will be disclosed in periodic reports [6]

Group 1 - The company has conducted a review of the list of incentive recipients for the 2025 stock option incentive plan, ensuring compliance with relevant laws and regulations [1][2] - The review confirmed that the selected incentive recipients meet the criteria set forth in the company's incentive plan draft and applicable regulations [2] - The company plans to grant 300,000 stock options to 5 incentive recipients on August 25, 2025, with an exercise price of 57.689 yuan per share [2] Group 2 - The monitoring committee outlined specific disqualifications for incentive recipients, including recent inappropriate designations by the stock exchange or regulatory bodies, and legal restrictions [1] - The committee's opinion supports the alignment of the incentive recipients with the standards approved in the company's first extraordinary general meeting of 2025 [2]

Group 1 - The company has established an incentive plan that includes a list of key personnel who will receive stock options [1] - A total of 120,000 stock options are allocated to 14 core personnel, representing 11.11% of the total options granted [1] - The allocation of stock options to core personnel constitutes 0.17% of the total amount planned for the incentive program [1] Group 2 - The list of key personnel includes core staff and other individuals deemed necessary for motivation by the board of directors, with no specific ranking provided [1]

| 司 | | | --- | --- | | 公司业绩考核要求： 2024 年营业收入 | 业收入平均值为 | | 三 第二个行权期业绩考核目标：以 2018-2020 年营业收 | 735,597.77 万元，较 | | 入均值为基数，2024 年营业收入增长率不低于 120%。 | 2018 年-2020 年营业 | | 收 入 均 值 增 长 | | | 业绩考核达成。 | | | 各业务单元/部门层面绩效考核要求： | | | 激励对象当年实际可行权的股票期权数量与其所属 | | | 业务单元/部门层面绩效考核相挂钩，各业务单元/部门层 | | | 面的绩效考核内容、方法、目标由公司决定。本激励计划 | 公司各业务单元/部 | | 授予的股票期权，在考核期内分年度对各业务单元/部门层 | 门层面绩效考核均 | | 四 面进行绩效考核，所属业务单元/部门层面绩效考核必须达 | 达标，满足各业务单 | | 标作为该业务单元/部门内激励对象的行权条件。 | 元/部门层面行权条 | | 期权的行权条件达成，则该业务单元/部门内激励对 | 件。 | | 象按照计划规定比例行权。反之，若行权条件未达成，则 | ...

本激励计划有效期自股票期权授权之日起至激励对象获授的股票期权全部行权或注销之日止，最长不超 过60个月。 格隆汇8月22日丨晶澳科技(002459.SZ)公布2025年股票期权激励计划(草案)，本激励计划拟向激励对象 授予的股票期权数量16,177.6185万份，约占本激励计划草案公告时公司股本总额330,968.16万股的 4.89%。本激励计划权益为一次性授予，无预留权益。本激励计划授予股票期权的行权价格为9.15元/ 份。 本激励计划由公司及与激励对象签署劳动合同的控股子公司作为实施主体，参与对象为公司(含控股子 公司)董事、高级管理人员、核心技术人员以及核心骨干人员，共计1,975人。 ...

Core Viewpoint - Shanghai Fosun Pharmaceutical Group Co., Ltd. has approved the draft of the 2025 A-share stock option incentive plan to enhance corporate governance and attract talent, aligning the interests of shareholders, the company, and its core team [1][2][5] Group 1: A-share Stock Option Incentive Plan - The board of directors approved the 2025 A-share stock option incentive plan draft and its summary, which aims to establish a long-term incentive mechanism [1][2] - The board's voting results showed unanimous support with 7 votes in favor, 0 against, and 0 abstentions [2][5] - The plan requires approval from the shareholders' meeting to be implemented [2][3] Group 2: Implementation and Management - The board also approved the implementation assessment management measures for the 2025 A-share stock option plan, which will be submitted for shareholder approval [3][4] - The board's voting results for the assessment management measures were also unanimous with 7 votes in favor, 0 against, and 0 abstentions [3][5] Group 3: Authorization for Related Matters - The board proposed to authorize itself to handle matters related to the 2025 A-share option plan, including the number of options and grant dates, subject to shareholder approval [4][5] - The authorization includes necessary actions such as signing grant agreements and applying for registration with relevant authorities [4][7] Group 4: H-share Restricted Stock Unit Plan - The board approved the draft of the 2025 H-share restricted stock unit plan, aimed at further improving corporate governance and retaining talent [5][6] - The plan will also require shareholder approval, and the board will determine the grant date after the plan is adopted [5][6] Group 5: Authorization for H-share Plan - The board proposed to authorize itself to manage matters related to the 2025 H-share restricted stock unit plan, including the number of units granted and the grant date [6][7] - The voting results for this authorization were unanimous with 7 votes in favor, 0 against, and 0 abstentions [6][8]